Patient selection is crucial, as individuals with addictive tendencies or personality disorders may not respond well to Spravato.

Common side effects of Spravato include dissociation, dizziness, and nausea, though these typically lessen after the initial treatment sessions.

The treatment is praised for its rapid effects, with some patients experiencing improvement within just two sessions.

During treatment, patients self-administer the nasal spray in a supervised clinic environment, often enjoying music and dim lighting to enhance their recovery experience.

Spravato, a nasal spray formulation of esketamine, has become a mainstream treatment option for treatment-resistant depression since its authorization by the Health Sciences Authority in October 2020.

The financial burden of treatment can be significant, with total costs potentially reaching tens of thousands of dollars, and many insurance plans do not cover it.

Due to its relatively new status and specific use cases, patients often have to pay out-of-pocket for Spravato, as many insurance companies do not provide coverage.

Despite the high cost of approximately $1,000 per session, some patients report life-changing benefits, including improved mental health and job opportunities.

Spravato is particularly effective for patients who have not responded to two or more antidepressant medications or are at risk of suicide.

Initially known as a horse tranquilizer and party drug, ketamine has emerged as an effective treatment for severe depression in Singapore, with significant success reported by psychiatrists.

Five psychiatrists have noted substantial success rates with Spravato, with four indicating that the majority of their patients achieved remission or recovery.

Johnson & Johnson, the manufacturer of Spravato, reported $780 million in sales for the drug in the first nine months of 2024, projecting it to become a 'blockbuster drug' with annual sales exceeding $1 billion.